Genome Expression Study (highly recommended when it's time for a biopsy)

Rationale: The observed variability in the clinical course of follicular lymphoma, along with the diverse range of therapeutic options available,  makes it necessary for more refined  diagnostic stratification  (such as by gene expression or cytogenetic differences in the tumor cells).

Conditions: Lymphoma; Leukemia; Multiple Myeloma; Lymphoid Malignancies

Locations: 
  Nebraska Medical Center in Omaha,  
  Southwest Oncology Group centers- see for centers http://www.swog.org/ 
  the British Columbia Cancer Agency in Vancouver, Canada; 
  the Norwegian Radium Hospital in Oslo, Norway; 
  the University of Würzburg in Würzburg, Germany; 
  the University of Barcelona in Barcelona, Spain; and 
  St. Bartholomew's Hospital in London, England.

Background:  The Leukemia and Lymphoma Molecular Profiling Project (LLMPP), a collaboration of researchers in the United States, Canada, and Europe NCI investigators are working with researchers at the University of Nebraska Medical Center in Omaha to define the gene expression profiles of all types of human lymphoid malignancies. 

The project is supported by an international collaboration ...  The LLMPP uses "Lymphochip" cDNA (complementary DNA) microarrays, which are enriched in genes that are expressed in and/or function in lymphocytes. Lymphochip microarrays allow measurement of the RNA expression levels of the represented genes. Gene expression profiles developed as a result of this project may someday be used for disease classification (diagnosis), prognosis, and therapy selection. Already, results from the LLMPP indicate that these profiles can improve diagnostic accuracy and provide prognostic information. 

The LLMPP is initiating a multicenter clinical trial to evaluate a lymphoma diagnostic chip, called LymphDX, which was designed by the company Affymetrix in collaboration with NCI researchers using LLMPP data. The study will demonstrate the feasibility of disseminating the LymphDX microarray technology to all of the participating sites and will also evaluate the diagnostic utility of the LymphDX chip in a prospective study.

Source: cancer.gov  

Genetic Study of Chronic Lymphocytic Leukemia Families
 
Condition: CLL 
 
Location: U.T.M.D. Anderson Cancer Center, Houston,  Texas

Genetic Studies of X-Linked Lymphoproliferative Disease
 
Conditions: X-Linked Lymphoproliferative Disease; Lymphoproliferative Disease; Genetic Diseases, X-Linked

An Observational Study of Treatment, Outcomes, and Prognosis 
 
Condition: Lymphoma, Non Hodgkin

A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients 
 
Condition: Non-Hodgkins Lymphoma

Prospective Data Collection of Newly Diagnosed Cases
 
Conditions: Hodgkin Disease; Lymphoma, Non-Hodgkin

A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL).
 
Condition: Hodgkin Lymphoma

Study of Late-Occurring Complications in Childhood Cancer Survivors
 
Condition: Cancer

Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant
 
Condition: Cancer

Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors   

to identify chronic health conditions, psychological disease, quality of life issues, and patient preferences for survivorship care in patients who have survived aggressive lymphoma.

Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
 
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; ...

Nutritional Assessment Intervention to Improve Cancer-Related Fatigue
 
Conditions: Leukemia; Lymphoma; Fatigue

Dual Time Point PET Imaging in Lymphoma
 
Condition: Hodgkin's or Non-Hodgkin's Lymphoma

Screening Patients With Central Nervous System Tumors for Participation in National Cancer Institute Clinical Trials
 
Conditions: Brain and Central Nervous System Tumors; Lymphoma